Docetaxel versus paclitaxel in the adjuvant setting : translating SABCS into clinical practiceRAVDIN, Peter.European journal of cancer. Supplement (1990). 2006, Vol 4, Num 5, pp 13-17, issn 1359-6349, 5 p.Article

Prognosis of patients with resected non-small cell lung cancer : Impact of clinical and pathologic variablesRAVDIN, Peter M; DAVIS, Gregory.Lung cancer. 2006, Vol 52, Num 2, pp 207-212, issn 0169-5002, 6 p.Article

Management of Breast Cancer : A New Therapeutic Approach. SymposiumLATREILLE, Jean; RAVDIN, Peter M.Seminars in oncology. 1995, Vol 22, Num 6, issn 0093-7754, 42 p., SUP13Conference Proceedings

The use of HER2 testing in the management of breast cancerRAVDIN, Peter.Seminars in oncology. 2000, Vol 27, Num 5, pp 33-42, issn 0093-7754, SUP9Conference Paper

Docetaxel (Taxotere) : An overview of first-line monotherapyTRUDEAU, M. E.Seminars in oncology. 1995, Vol 22, Num 6, pp 17-21, issn 0093-7754, SUP13Conference Paper

Hormone Replacement Therapy and the Increase in the Incidence of Invasive Lobular CancerRAVDIN, Peter M.Breast disease. 2008, Vol 30, pp 3-8, issn 0888-6008, 6 p.Article

Taxoids : Effective agents in anthracycline-resistant breast cancerRAVDIN, P. M.Seminars in oncology. 1995, Vol 22, Num 6, pp 29-34, issn 0093-7754, SUP13Conference Paper

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerHARRIS, Lyndsay; FRITSCHE, Herbert; MENNEL, Robert et al.Journal of clinical oncology. 2007, Vol 25, Num 33, pp 5287-5312, issn 0732-183X, 26 p.Article

Choosing between endocrine therapy and chemotherapy - or is there a role for combination therapy?FORBES, John F; GRADISHAR, William J; RAVDIN, Peter M et al.Breast cancer research and treatment. 2002, Vol 75, pp S37-S44, issn 0167-6806, SUP1Article

Docetaxel (Taxotere) : An effective agent in the management of second-line breast cancerVAN OOSTEROM, A. T.Seminars in oncology. 1995, Vol 22, Num 6, pp 22-28, issn 0093-7754, SUP13Conference Paper

Patterns of Treatment for Early Stage Breast Cancers at the M. D. Anderson Cancer Center From 1997 to 2004YU SHEN; WENLI DONG; FEIG, Barry W et al.Cancer. 2009, Vol 115, Num 10, pp 2041-2051, issn 0008-543X, 11 p.Article

Poor-Prognosis Estrogen Receptor-Positive Breast Cancer Identified by Histopathologic SubclassificationWEBSTER, Lucy R; LEE, Shu-Fen; GREEN, Andrew R et al.Clinical cancer research (Print). 2008, Vol 14, Num 20, pp 6625-6633, issn 1078-0432, 9 p.Article

Preclinical profile of docetaxel (Taxotere) : Efficacy as a single agent and in combinationBISSERY, M.-C; VRIGNAUD, P; LAVELLE, F et al.Seminars in oncology. 1995, Vol 22, Num 6, pp 3-16, issn 0093-7754, SUP13Conference Paper

Prediction Model for Estimating the Survival Benefit of Adjuvant Radiotherapy for Gallbladder CancerWANG, Samuel J; FULLER, C. David; KIM, Jong-Sung et al.Journal of clinical oncology. 2008, Vol 26, Num 13, pp 2112-2117, issn 0732-183X, 6 p.Article

The decrease in breast-cancer incidence in 2003 in the United StatesRAVDIN, Peter M; CRONIN, Kathleen A; HOWLADER, Nadia et al.The New England journal of medicine. 2007, Vol 356, Num 16, pp 1670-1674, issn 0028-4793, 5 p.Article

Population-based validation of the prognostic model ADJUVANT! for early breast cancerOLIVOTTO, Ivo A; BAJDIK, Chris D; RAVDIN, Peter M et al.Journal of clinical oncology. 2005, Vol 23, Num 12, pp 2716-2725, issn 0732-183X, 10 p.Article

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer : Treatment results of intergroup protocol INT-0102HUTCHINS, Laura F; GREEN, Stephanie J; RAVDIN, Peter M et al.Journal of clinical oncology. 2005, Vol 23, Num 33, pp 8313-8321, issn 0732-183X, 9 p.Conference Paper

Independent Prognostic Value of Screen Detection in Invasive Breast CancerMOOK, Stella; VAN 'T VEER, Laura J; RUTGERS, Emiel J et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 7, pp 585-597, issn 0027-8874, 13 p.Article

A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancerLYMAN, Gary H; GREEN, Stephanie J; RAVDIN, Peter M et al.Breast cancer research and treatment. 2004, Vol 85, Num 2, pp 143-150, issn 0167-6806, 8 p.Article

Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic FeaturesGOLDSTEIN, Lori J; GRAY, Robert; SLEDGE, George W et al.Journal of clinical oncology. 2008, Vol 26, Num 25, pp 4063-4071, issn 0732-183X, 9 p.Article

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal WomenCHLEBOWSKI, Rowan T; KULLER, Lewis H; RAJKOVIC, Aleksandar et al.The New England journal of medicine. 2009, Vol 360, Num 6, pp 573-587, issn 0028-4793, 15 p.Article

Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial TissuesRIMM, David L; NIELSEN, Torsten O; MAGLIOCCO, Anthony M et al.Journal of clinical oncology. 2011, Vol 29, Num 16, pp 2282-2290, issn 0732-183X, 9 p.Article

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal WomenCHLEBOWSKI, Rowan T; ANDERSON, Garnet L; JOHNSON, Karen C et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 15, pp 1684-1692, issn 0098-7484, 9 p.Article

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancerSONG YAO; BARLOW, William E; RAVDIN, Peter M et al.Breast cancer research and treatment. 2010, Vol 124, Num 2, pp 433-439, issn 0167-6806, 7 p.Article

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerSONG YAO; BARLOW, William E; RAVDIN, Peter M et al.Clinical cancer research (Print). 2010, Vol 16, Num 24, pp 6169-6176, issn 1078-0432, 8 p.Article